Sonidegib for laBCC: A Neoadjuvant Game Changer?
Neoadjuvant Hedgehog Pathway Inhibitors (HPIs) are reshaping the approach to locally advanced basal cell carcinoma (laBCC), but tolerability remains a concern. A recent case highlights successful tumor reduction with sonidegib before Mohs surgery—achieving optimal results with minimal side effects. Could this be the key to better outcomes in cosmetically sensitive areas?
